Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Tag: MONOGRAPH

Oxytocin

Plain-language summaryIntrigue 72 / 100

Oxytocin is the social bonding and childbirth hormone, a 9-amino-acid peptide. Used clinically to induce labor and control postpartum bleeding. Off-label and research interest in social bonding, autism spectrum disorders, and PTSD. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

39/100

Canonical OTR probe with clean obstetric evidence; intranasal CNS research has largely underdelivered

Look, oxytocin is one of those compounds where the story sounds better than the data actually reads. It’s an endogenous nonapeptide, hypothalamic origin, posterior pituitary release. The basic biology has been textbook for decades. The FDA approval for labor induction and postpartum hemorrhage is real and well-earned; that translational arrow is clean and strong. But that’s not why most research groups are pulling it off the shelf today.

The interesting research angle has been intranasal oxytocin for autism spectrum disorder, PTSD, social anxiety, and pair bonding. This has been one of the more disappointing stories in translational neuropharmacology over the last fifteen years. The Simon Baron-Cohen and Ernst Fehr groups generated genuinely exciting early data around 2010-2013 on social cognition and trust behavior. The mechanism story was compelling: OTR activation in the amygdala modulating threat appraisal, OTR in the nucleus accumbens influencing reward-based social behavior. It made sense on paper.

Then replication hit this literature hard. The Bethlehem et al. (2017) Lancet Psychiatry RCT in ASD, multi-site and well-powered, didn’t find meaningful benefit. The Guastella group’s replication work showed high effect-size heterogeneity across studies. The core problem, which still isnt resolved, is whether intranasal oxytocin actually reaches the brain in meaningful concentrations. Some investigators argue it acts peripherally on vagal afferents and OTR in circumventricular organs. Others think direct CNS entry occurs but in a dose and individual-variable manner. That debate is live and unresolved, and it cuts directly at the bench utility of the compound for the programs investigators care about most.

We think the bench value remains real for specific programs. If you’re running a social behavior study in rodents, investigating OTR distribution, or studying parturition physiology, oxytocin is what you need and thats not changing. The pharmacology around OTR subtypes, signal bias, and receptor trafficking is genuinely active and underexplored at the mechanistic level. What we dont like is the enthusiasm that still surrounds the psychiatric indications given how consistently those trials have underperformed.

The mechanism is single-receptor, known for decades, not unusual. Differentiation is structural: it’s the canonical OTR agonist and theres no real alternative probe, but that’s a position of necessity rather than pharmacological innovation. Evidence quality overall sits high because of the approved use and massive literature base, but for the research indications most investigators actually care about, the signal is frankly thin. Oxytocin belongs in your library if you’re doing OTR biology or reproductive physiology; for social cognition and psychiatric programs, honest assessment suggests the field has more questions than answers, and the translational promise hasn’t materialized.

Novelty

22

Mechanism promise

30

In-category differentiation

45

Evidence quality

60

Translational signal

35

Research bench value

55

Rationale Oxytocin is the reference compound for OTR biology with a massive, FDA-backed evidence base in reproductive medicine, but the headline research angle (intranasal delivery for autism, PTSD, social cognition) has produced mixed-to-negative results across multiple large RCTs, and CNS penetration after intranasal administration remains mechanistically contested, deflating novelty, mechanism, and translational scores significantly.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Endogenous nonapeptide neuropeptide/hormone

An endogenous nonapeptide produced in the hypothalamus and released by the posterior pituitary, with maternal, social bonding, and anxiolytic effects.

Abstract

Oxytocin (CAS 50-56-6; molecular formula C43H66N12O12S2; molecular weight 1007.19) is an endogenous nonapeptide hormone synthesized in the paraventricular and supraoptic nuclei of the hypothalamus and released systemically by the posterior pituitary. The compound is FDA-approved for labor induction and postpartum hemorrhage (intravenous). Beyond reproductive applications, intranasal oxytocin has been studied extensively for autism spectrum disorder, social anxiety, PTSD, and pair bonding research, with mixed clinical results. Mechanism is oxytocin receptor (OTR) agonism. Pharmacokinetics: plasma half-life ~3 to 6 minutes; central CNS penetration after intranasal administration is debated. Doses for research applications are typically 24 IU intranasally per administration.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-135Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Lemborexant

Plain-language summaryIntrigue 72 / 100

Lemborexant, sold as Dayvigo, is a second-generation dual orexin receptor antagonist with improved selectivity for OX2 over OX1. FDA-approved for insomnia in 2019. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

45/100

Second DORA with refined PK but no novel mechanism; useful clinically, limited bench excitement

Look, the DORA class is genuinely interesting biology. Blocking orexin signaling to let sleep initiate naturally is a fundamentally more elegant approach than hammering GABA-A with benzos or Z-drugs, and the orexin system touches enough downstream biology (metabolism, reward, arousal, thermoregulation) that serious investigators are still mapping its reach. We like that framing. The problem is that suvorexant already got there in 2014, established the mechanism, and built the early research scaffolding. Lemborexant is the second car in the lot.

The clinical differentiation is real but modest. Lemborexant has a somewhat faster-declining active fraction than suvorexant, which translated into statistically improved next-day psychomotor performance in the SUNRISE-1 and SUNRISE-2 trials. Eisai ran solid Phase 3 RCTs; the FDA approved it in 2019. Evidence quality is genuinely good for an insomnia drug, and the clinical signal is clear: it works, it’s well-tolerated, next-day grogginess is less of a problem than with older agents. That earns points. But those points are clinical pharmacology points, not research frontier points.

Here’s the thing: from a bench perspective, what does lemborexant let you do that suvorexant doesn’t? Both are competitive dual OX1R/OX2R antagonists. If you’re using a DORA as a probe to dissect orexin circuit biology, suvorexant has a larger research literature behind it and more years of investigator familiarity. Daridorexant (Quviviq) arrived in 2022 with additional comparative data. Lemborexant sits in the middle of a growing class without claiming either first-mover status or uniquely differentiated pharmacology. For any serious research program building around orexin biology, theres more leverage in selective OX1R or OX2R ligands (SB-334867, EMPA, JNJ-61393178) than in a second-in-class approved DORA.

We don’t want to dismiss the compound entirely. The orexin system research space is active and still has real open questions: the OX1R-versus-OX2R contribution to different sleep architecture features, cross-talk with the HPA axis, the metabolic regulation angle. A well-characterized approved DORA does have utility as a reference compound in that work. But lemborexant specifically adds little that suvorexant doesn’t already provide as a probe, and that limits its research bench value meaningfully.

Honestly, this is a compound that belongs in a clinical pharmacist’s formulary more than on a research scientist’s priority list. The score reflects a real, approved, well-evidenced drug with solid mechanism credentials in a class that matters, discounted heavily for being second-in-class with no novel angle worth chasing in 2024 bench science.

Novelty

35

Mechanism promise

52

In-category differentiation

28

Evidence quality

72

Translational signal

58

Research bench value

28

Rationale Lemborexant earns real marks for solid Phase 3 RCT evidence and a mechanistically elegant class (DORA), but it’s the second approved compound in a mechanism suvorexant already pioneered, and its differentiation story is almost entirely pharmacokinetic rather than pharmacodynamic. The schedule IV cap (75 max) doesn’t bind since the rubric naturally lands well below it.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Dual orexin receptor antagonist

A second DORA FDA-approved as Dayvigo (2019) for insomnia, with shorter half-life and reduced next-day residual effects than suvorexant.

Abstract

Lemborexant (Dayvigo; E2006; CAS 1369764-02-2) is a dual orexin receptor antagonist developed by Eisai and approved by the FDA in 2019 for insomnia. The compound has shorter plasma half-life (17 to 19 hours, but the active fraction declines more rapidly than with suvorexant) and reduced next-day residual sedation in clinical trials. Mechanism is the same as suvorexant: competitive OX1R and OX2R antagonism. Approved doses are 5 to 10 mg at bedtime. Schedule IV.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-151Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Dynamine (Methylliberine)

Plain-language summaryIntrigue 38 / 100

Dynamine (methylliberine) is a purine alkaloid related to theacrine, marketed in pre-workout formulations as a longer-lasting alternative to caffeine. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundOverhyped vs evidence

22/100

Proprietary purine alkaloid with derivative caffeine-like mechanism and manufacturer-funded evidence base

Look, Dynamine is a supplement industry compound first and a research target second. Methylliberine is a purine alkaloid isolated from kucha tea, a close structural relative of theacrine and, further up the family tree, caffeine. The proposed mechanism is adenosine receptor antagonism, which puts it squarely in one of the most thoroughly worked territories in pharmacology. When your mechanism is “probably like caffeine but maybe a bit faster,” you’re not giving a bench scientist much to get excited about.

The compound’s commercial origin shapes everything about the evidence base. Compound Solutions holds the trademark on Dynamine, and most of the available research is either funded by or conducted in direct collaboration with the licensor. There are a handful of small, acute studies examining subjective energy and focus outcomes in healthy adults; the designs are typically crossover, N is small, and independent replication is essentially absent. The “faster onset than theacrine” claim reads like a product differentiation pitch rather than a mechanistic finding that tells you anything actionable about the underlying pharmacology.

Here’s what we actually dont know: the full receptor binding profile. The adenosine antagonist claim is plausible given structural similarity to caffeine and theacrine, but specific affinity data for A1 and A2A subtypes is not clearly available in the open literature. That ambiguity might sound like a research opportunity. It isn’t. It’s more likely a sign that no serious academic group has prioritized the question in the seven-plus years since the ingredient was introduced to market. When industry-funded compounds fail to generate independent academic traction in that window, the absence is informative.

For probe value, caffeine remains the gold-standard adenosine antagonist for bench work, with decades of receptor binding data, knockout models, and well-characterized dose-response relationships behind it. If you’re doing A2A biology, you have better tools. If you’re interested in comparative pharmacokinetics within the purine alkaloid class, theacrine’s tolerance profile has at least generated some independent investigation; methylliberine’s PK data is thin. There’s no assay, no pathway, no model system where Dynamine opens a door that better-characterized compounds don’t already open more cleanly.

We don’t think this earns shelf space in a serious research library. It’s a trademarked supplement ingredient backed by a handful of company-sponsored trials and a plausible but uncharacterized mechanism. If the purine alkaloid space genuinely interests you, the research resources are better spent on theacrine’s habituation biology or the broader adenosine receptor field, where actual frontier work is happening.

Novelty

32

Mechanism promise

18

In-category differentiation

20

Evidence quality

18

Translational signal

22

Research bench value

18

Rationale Methylliberine’s proposed mechanism is adenosine antagonism, pharmacologically indistinguishable in kind from caffeine and theacrine, and the evidence base is almost entirely licensor-funded with no meaningful independent replication. The compound earns modest novelty points for being a relatively recent structural variant, but nothing in the available literature justifies prioritizing it over better-characterized tools in the same class.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Purine alkaloid (methylliberine)

A purine alkaloid related to theacrine, present in kucha tea, marketed as Dynamine for energy and focus applications.

Abstract

Dynamine (methylliberine; 9-methylliberine) is a purine alkaloid related to theacrine and present in kucha tea (Camellia kucha). The compound is marketed as Dynamine by Compound Solutions for energy and focus applications. Pharmacology likely overlaps with the broader methylxanthine class (adenosine antagonism) but specific receptor profile and clinical evidence base are limited. Doses are typically 50 to 200 mg per administration; Compound Solutions describes it as having faster onset than theacrine.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-166Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Taurine

Plain-language summaryIntrigue 60 / 100

Taurine is a sulfonate amino acid abundant in heart, retina, and brain. Conditional rather than essential (the body makes it from cysteine). Has cardioprotective, anti-inflammatory, and GABAergic effects. Found in energy drinks where the contribution to performance is contested. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundBasic amino acid

32/100

Basic endogenous sulfonate with an interesting 2023 longevity paper but fundamentally mature and low bench priority

Cap applied basic amino acid cap (32)

Yeah, taurine. The Singh et al. 2023 Science paper put this on a lot of radars, and we get why. A multi-species lifespan and healthspan study in a top journal, showing that plasma taurine declines with age and that supplementation partially reverses that decline in mice, worms, and cynomolgus monkeys, thats genuinely interesting. We’re not dismissing it.

But here’s the thing: taurine is still an endogenous sulfonate that’s been in the literature since the 1970s. It’s in energy drinks. Your cat food is fortified with it. The mechanisms, including bile acid conjugation, osmotic regulation, calcium handling in cardiac tissue, and modulation of GABA and glycine receptor activity, are textbook biology at this point. None of that is novel territory, and none of it gives an investigator a new handle on a hard problem.

What the Singh paper actually does is give an old compound a new frame: if circulating taurine is a biomarker of biological aging, and supplementation restores youthful levels, then you have a plausible longevity rationale that wasn’t clearly articulated before. The effect sizes in mice were meaningful, around 10 to 12 percent lifespan extension, and the monkey healthspan marker data is intriguing. But the human arm of that study was observational, not interventional. There is no RCT demonstrating human longevity benefit, and the bench-to-clinic gap for longevity endpoints is one of the hardest translation problems in the field.

The cardiovascular and exercise literature is older and reasonably solid. Taurine has real roles in cardiac calcium handling; there’s clinical evidence for benefits in heart failure patients at gram-level doses. The exercise literature is mixed. None of it is particularly surprising given the known mechanisms.

As a research tool, taurine has limited probe value. If you’re studying GABAergic or glycinergic neurotransmission, there are more selective tools. If you’re studying longevity pathways, MOTS-c, rapamycin, or even GLP-1 class compounds offer more mechanistic traction. Taurine’s bench utility is mostly in confirming effects you already suspect rather than uncovering new biology.

Honestly, if you’re building a research program around the Singh findings, the interesting question isn’t whether taurine supplementation does something, but why taurine declines with age and what upstream process drives that. Taurine itself is probably not the most productive research object. The 2023 paper is a pointer, not a destination, and at Kodiac we’d deprioritize this one relative to compounds with genuinely novel mechanisms or more compelling human interventional evidence.

Novelty

26

Mechanism promise

30

In-category differentiation

20

Evidence quality

55

Translational signal

40

Research bench value

35

Rationale Singh et al. 2023 (Science) gives taurine a genuine new angle with multi-species lifespan data and the plasma-decline-with-age framing, pushing evidence and translational scores above floor; however, the compound is still an endogenous sulfonate with textbook-level mechanisms and no human interventional longevity RCT, so the raw overall clears the basic-aa cap and the cap binds at 32.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Conditional amino acid / sulfonate

An endogenous sulfonate amino acid with osmolyte, calcium-handling, and bile acid conjugation roles, recently associated with longevity in animal models.

Abstract

Taurine (2-aminoethanesulfonic acid; CAS 107-35-7; molecular formula C2H7NO3S; molecular weight 125.15) is an endogenous sulfonate “amino acid” (taurine has a sulfonate group rather than a carboxylate) with widespread tissue distribution and multiple physiological roles: bile acid conjugation, osmotic regulation, calcium handling in cardiac tissue, and modulation of GABA and glycine neurotransmission. Plasma taurine declines with age. A 2023 Science paper (Singh et al.) demonstrated that taurine supplementation extends lifespan and healthspan in mice, monkeys, and worms; the result generated significant interest in taurine as a longevity intervention. Doses for longevity applications are typically 3 to 6 grams per day; doses for cardiovascular and exercise applications are 1 to 6 grams. Excellent safety profile.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-182Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
1,2,3,4-Tetrahydroisoquinoline (THIQ)

Plain-language summaryIntrigue 45 / 100

1,2,3,4-Tetrahydroisoquinoline (THIQ) is an endogenous and exogenous alkaloid with research interest in dopaminergic systems and neurodegenerative disease. The compound and its derivatives are studied as Parkinson disease research tools. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Endogenous and exogenous alkaloid

A simple isoquinoline scaffold present endogenously and as a structural element of many alkaloid pharmacophores; also studied for MAO modulation.

Abstract

1,2,3,4-Tetrahydroisoquinoline (THIQ; CAS 91-21-4; molecular formula C9H11N; molecular weight 133.19) is a simple isoquinoline alkaloid scaffold present endogenously in mammalian brain (formed by Pictet-Spengler condensation of phenethylamine and formaldehyde or related aldehydes) and as a structural component of many pharmacological alkaloids. Endogenous THIQs are implicated in some neurodegenerative processes (the 1-methyl-THIQ derivative is structurally similar to MPTP, the Parkinsonism-inducing toxin). The unsubstituted THIQ has been studied as a research probe for monoamine oxidase modulation and dopaminergic system effects. Not in clinical use.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-199Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Mianserin

Plain-language summaryIntrigue 47 / 100

Mianserin is the older European cousin of mirtazapine, developed at Organon in the 1960s and marketed across Europe and Asia from 1976 onward. It was never approved in the United States. Like mirtazapine it boosts norepinephrine and serotonin output by blocking the auto-brake on those neurons rather than blocking the reuptake pumps. The differences are subtle: mianserin has a wider spread of off-target receptor activity and a small but historically significant risk of bone marrow suppression, which is part of why mirtazapine ultimately replaced it in most markets. Mianserin remains useful as a research tool for understanding the alpha-2 adrenergic receptor mechanism. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

33/100

Superseded tetracyclic antidepressant with limited modern research appeal beyond mirtazapine comparison work

Look, mianserin is the compound mirtazapine quietly replaced. Organon developed it in the 1960s, got it onto the European and Asian market in 1976, and then spent the next two decades iterating toward a safer, cleaner successor. That successor is mirtazapine. The story of mianserin is, in a meaningful sense, the story of what had to be fixed to get there.

The mechanism is genuinely interesting in outline: alpha-2 adrenergic auto- and heteroreceptor antagonism drives monoaminergic disinhibition in a way thats actually pharmacologically elegant compared to older tricyclics. You also get 5-HT2A, 5-HT2C, H1, and alpha-1 antagonism in the mix. But every one of those receptor interactions is better characterized in mirtazapine, and mirtazapine does it without the agranulocytosis and aplastic anemia risk that haunted mianserin’s clinical career — estimated at roughly 1 in 1500 to 1 in 5000 cases, which is hard to ignore when a structurally similar compound with a cleaner safety profile exists.

The evidence base is real. Decades of European clinical use, multiple controlled trials, established PK (half-life 21-61 hours, CYP2D6 metabolism, active demethyl-mianserin metabolite). This isnt a compound with thin preclinical-only data. But the evidence is aging, the trials are mostly pre-2000, and virtually no active research programs are centering mianserin as a primary object of study. The literature is large because it was used, not because researchers are still reaching for it.

What bench value mianserin retains is narrow. It works as a reference compound in alpha-2 pharmacology comparisons and as a historical control when studying tetracyclic antidepressant mechanisms. If your research question specifically involves comparing first- versus second-generation tetracyclics, or quantifying the receptor-selectivity improvements that mirtazapine achieved, then mianserin is the natural comparator. Outside that framing, its hard to construct a reason to run an experiment with mianserin when mirtazapine exists and is more widely available.

We dont think this belongs on a frontier research shortlist. The novelty is low, the differentiation is negative relative to its own successor, and the research signal it carries is historical rather than prospective. Serious investigators working in adrenergic or tetracyclic antidepressant pharmacology probably already know where mianserin fits. For anyone else, the compound earns a file entry and not much more.

Novelty

18

Mechanism promise

28

In-category differentiation

18

Evidence quality

58

Translational signal

55

Research bench value

30

Rationale Mianserin’s core mechanism is well-understood and has been materially improved upon by mirtazapine, which retains the pharmacologically interesting alpha-2 antagonism while shedding the agranulocytosis liability; novelty and differentiation scores drag the overall down hard. Evidence quality and translational signal are real but historically bounded and largely irrelevant to active research programs.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Tetracyclic alpha-2 adrenergic antagonist

A first-generation tetracyclic antidepressant; the structural and mechanistic precursor to mirtazapine.

Abstract

Mianserin (1,2,3,4,10,14b-hexahydro-2-methyldibenzo[c,f]pyrazino[1,2-a]azepine; CAS 24219-97-4; molecular formula C18H20N2; molecular weight 264.37) is a tetracyclic antidepressant developed at Organon in the 1960s and marketed in Europe and Asia from 1976 (never FDA approved for the US market). The compound is the structural and mechanistic precursor to mirtazapine, sharing the alpha-2 adrenergic auto/heteroreceptor antagonism that increases monoaminergic release. Mianserin additionally exhibits 5-HT2A, 5-HT2C, H1, and alpha-1 antagonism but with a less favorable receptor selectivity profile than mirtazapine. Notable for a higher incidence of agranulocytosis and aplastic anemia than mirtazapine (estimated 1 in 1500 to 1 in 5000 cases) which contributed to its replacement in clinical practice. Plasma half-life is 21 to 61 hours; metabolism is via CYP2D6 with active demethyl-mianserin metabolite. Used as a reference tetracyclic and alpha-2 antagonist in mechanism studies; less common in clinical use today owing to mirtazapine availability.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-214Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Sembragiline

Plain-language summaryIntrigue 40 / 100

Sembragiline is an investigational selective reversible MAO-B inhibitor from Roche and EVOTEC, originally developed as a possible Alzheimer disease treatment. The rationale was elegant: MAO-B is upregulated in the reactive astrocytes that surround amyloid plaques in Alzheimer brain tissue, and that upregulation contributes to oxidative damage. Selectively shutting it down with a reversible blocker should, in theory, reduce that damage without interfering with normal brain function. The Phase 2 MAyflOwer RoAD trial in mild-to-moderate Alzheimer disease failed to show clinical benefit, however, and development was halted. The compound retains research value as a mechanistic probe but has no clinical future. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

38/100

Failed Alzheimer phase 2 candidate with residual tool value as a clean reversible selective MAO-B probe

Look, sembragiline is a clean story about a drug that asked the right question and got the wrong answer. The mechanistic rationale was genuinely reasonable: MAO-B is upregulated in reactive astrocytes in Alzheimer brain tissue, it contributes to oxidative stress, and there’s a plausible chain from that to amyloid pathology. Roche and Evotec built a highly selective reversible inhibitor to probe this, with a selectivity ratio above 1000:1 over MAO-A. Thats pharmacologically elegant. The reversibility angle was the key idea: unlike selegiline or rasagiline, which ablate MAO-B activity for the life of the enzyme, sembragiline gives you tunable, titratable inhibition without committing to an irreversible mechanism.

Then the MAyflOwer RoAD trial happened. Phase 2, n=542, mild-to-moderate Alzheimer disease, 52 weeks. No significant slowing of cognitive decline. Development halted. The compound didn’t fail because of bad pharmacology; it failed because the hypothesis didn’t translate. MAO-B inhibition in Alzheimer’s turned out not to be a sufficient lever on disease progression, at least not at the population level or the dose ranges tested.

What’s left is a genuinely useful but narrow tool compound. Academic neuroscience groups use sembragiline specifically because of what it is: the reference reversible selective MAO-B inhibitor with the cleanest selectivity profile available. If you’re studying MAO-B’s contribution to neuroinflammatory signaling, dopamine metabolism in Parkinson’s-adjacent biology, or oxidative stress dynamics in reactive astrocytes, you need something that lets you toggle the enzyme without the complication of irreversibility. Safinamide is also reversible and approved, but it carries a sodium channel component that complicates clean mechanistic attribution. Sembragiline is cleaner for this purpose.

We think the bench value is real but specific. If your research program touches MAO-B biology directly, this is worth having and using. If it doesn’t, theres not much here. The failed phase 2 is decisive for the Alzheimer’s indication, and the compound has no obvious pivot to another indication with real human signal. Novelty is modest: MAO-B inhibition is a mature mechanistic class, and reversible selectivity within it is a refinement, not a new direction.

Honestly, what keeps this at 38 is arithmetic. The mechanism class is established, the clinical hypothesis was falsified, and the tool value is specific enough to matter only to a subset of neuroscience programs. Sembragiline ran a clean trial and learned something real. That’s exactly what research should do. It just doesn’t make the compound a priority target for most investigators, and the score should say so plainly.

Novelty

32

Mechanism promise

35

In-category differentiation

48

Evidence quality

44

Translational signal

22

Research bench value

55

Rationale Sembragiline’s mechanistic rationale was scientifically sound but the MAyflOwer RoAD trial (n=542, 52 weeks) produced a clear null result, decisively closing the AD indication. Its remaining value is as the reference reversible, highly selective MAO-B inhibitor (greater than 1000:1 over MAO-A) for academic studies of MAO-B’s contribution to neurodegeneration, but that utility is narrow enough that bench_value can’t rescue the overall from niche-probe territory.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Selective reversible MAO-B inhibitor (investigational)

A selective reversible MAO-B inhibitor investigated for Alzheimer disease; failed phase 2 efficacy.

Abstract

Sembragiline (EVT-302, RG1577; molecular formula C19H22FN3O; molecular weight 327.40) is a selective reversible MAO-B inhibitor developed at Roche and EVOTEC as a candidate for Alzheimer disease. The mechanistic rationale: MAO-B is upregulated in reactive astrocytes in Alzheimer brain tissue, contributing to oxidative stress and amyloid pathology; selective reversible inhibition might reduce this contribution without the irreversible enzyme abolition of selegiline or rasagiline. Phase 2 MAyflOwer RoAD trial in mild-to-moderate Alzheimer disease (n=542) failed to show significant slowing of cognitive decline at 52 weeks; development was halted. The compound retains research utility as a clean tool for selective reversible MAO-B inhibition (selectivity ratio greater than 1000:1 over MAO-A) and is used in academic studies of MAO-B’s role in neurodegeneration. Used as the reference reversible selective MAO-B inhibitor in academic neuroscience.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-231Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Vigabatrin

Plain-language summaryIntrigue 69 / 100

Vigabatrin (Sabril) is a so-called suicide inhibitor of GABA transaminase, the enzyme that breaks down the brain’s main inhibitory neurotransmitter. The vinyl group on the molecule converts vigabatrin into a fake substrate that the enzyme attempts to process and is then permanently destroyed by; the only way the brain restores normal GABA breakdown is to manufacture new enzyme from scratch. The result is sustained and powerful elevation of brain GABA levels. It is uniquely effective in infantile spasms (a devastating early-childhood seizure disorder) and refractory complex partial seizures. The catch is severe and irreversible: roughly a third of patients develop permanent visual field constriction from retinal toxicity. That has restricted it to cases where no alternative works. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

53/100

The canonical irreversible GABA-T suicide inhibitor, clinically validated but mechanistically mature and toxicity-constrained

Vigabatrin has been in the clinic since 1989 in Europe, with US approval following in 2009. That timeline matters for how you read the score. This isnt a compound at the frontier of anything; it’s a compound that already did its frontier work decades ago and has been in routine use ever since.

The mechanism is genuinely clever, and worth understanding on its own terms. The vinyl group at the alpha-carbon turns vigabatrin into a substrate that GABA transaminase begins to process but can’t release. The result is irreversible covalent inactivation of the enzyme, with GABA degradation capacity only restored by de novo enzyme synthesis. That makes the pharmacodynamic window substantially longer than the plasma half-life of 5 to 13 hours would suggest. As a piece of chemical biology, suicide inhibition is elegant; as a research tool, the irreversibility is actually useful for experiments requiring sustained, stable GABA-T suppression without continuous re-dosing.

The clinical translational story is real and worth acknowledging directly. For infantile spasms, specifically West syndrome, the treatment options are limited and vigabatrin is one of them. The UKISS trial and the pivotal FDA registration studies, particularly for tuberous sclerosis-associated spasms, showed meaningful seizure suppression where many anticonvulsants fail. That’s a durable human signal, not a preclinical artifact.

The problem, and it’s not a minor one, is the retinal toxicity. Bilateral concentric visual field constriction in roughly 30 to 50 percent of long-term users. Irreversible. The FDA REMS program exists because of this, mandating baseline and periodic visual field testing. Current research thinking attributes the damage to GABA accumulation in retinal photoreceptors. For bench investigators, this means any animal model work with vigabatrin has to account for retinal off-target effects as a confound.

We think vigabatrin earns a library spot specifically as a reference probe. If your research program touches GABA metabolism, inhibitory circuit modulation, or mechanism-based enzyme inhibition as a chemical strategy, vigabatrin is the standard. No other approved compound does what it does to GABA-T. What it doesnt offer is novelty, a growing literature edge, or any real frontier signal. The mechanistic questions are settled, the clinical niche is narrow, and the toxicity profile constrains enthusiasm for new indication discovery. A serious bench scientist working on GABAergic biology needs this compound; a scientist looking for their next interesting target probably doesnt start here.

Novelty

22

Mechanism promise

42

In-category differentiation

60

Evidence quality

76

Translational signal

70

Research bench value

65

Rationale Vigabatrin earns solid evidence and translational scores given FDA approval, REMS-backed safety surveillance, and real infantile spasms efficacy, but novelty is low for a compound with 35-plus years of literature and a fully characterized mechanism; primary research value now sits in its role as the definitive irreversible GABA-T probe for GABAergic circuit and enzyme kinetics work.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

GABA transaminase inhibitor (irreversible)

An irreversible suicide inhibitor of GABA transaminase; uniquely effective in infantile spasms and refractory complex partial seizures, limited by retinal toxicity.

Abstract

Vigabatrin ((R/S)-4-aminohex-5-enoic acid; CAS 60643-86-9; molecular formula C6H11NO2; molecular weight 129.16) is a vinyl-GABA suicide inhibitor of GABA transaminase developed at Marion Merrell Dow and approved by the FDA in 2009 under the trade name Sabril (later than European registration in 1989). Mechanism: the vinyl group at the alpha-carbon converts vigabatrin into a substrate that the GABA transaminase enzyme begins to process but cannot release; the result is irreversible covalent enzyme inactivation, requiring de novo enzyme synthesis to recover GABA degradation capacity. The consequence is sustained elevation of brain GABA concentrations. Effective in infantile spasms (West syndrome) where conventional anticonvulsants often fail, and as adjunctive therapy in refractory complex partial seizures. The principal limitation is irreversible bilateral concentric visual field constriction in approximately 30 to 50 percent of long-term users, attributed to retinal photoreceptor damage; the FDA REMS program requires baseline and periodic visual field assessment. Plasma half-life is 5 to 13 hours, but the irreversible enzyme inhibition produces effective activity beyond the plasma window. Used as the canonical GABA transaminase suicide inhibitor.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-246Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Testolone (RAD-140)

Our opinion on this compoundEstablished, active research

50/100

Highest-potency SARM with a real clinical trajectory in breast cancer, but mechanism maturity limits ceiling

RAD-140 is probably the most potent SARM in the research toolkit, and that does matter for how you use it on the bench. With a Ki around 7 nM and intrinsic activity that in some preclinical models exceeds testosterone propionate at equivalent molar doses, it’s not a subtle tool. The selectivity profile – meaningful anabolic activity with reduced androgenic effects in prostate tissue compared to steroidal androgens – is what got Radius Health interested in the first place, and it’s still the core value proposition.

The breast cancer angle is where things get genuinely interesting. AR-positive metastatic breast cancer is a real clinical problem with limited options, and the phase 1 data in postmenopausal women did show dose-dependent AR pathway engagement. The program moved into phase 2, which puts RAD-140 in a much smaller club than most SARMs that never get near a clinic. Thats worth noting when you’re assessing the translational signal here.

So why a 50? Honestly, the SARM mechanism is the limiting factor. Tissue-selective AR agonism is well-understood at this point – the co-activator recruitment story, the differential downstream signaling in muscle versus prostate, the axis suppression trade-offs. None of that is new. And the SARM space has been actively researched for long enough that what once felt genuinely novel now feels like a crowded field. RAD-140 is the highest-potency member of an increasingly mature class.

The evidence situation is better than most SARMs but still limited by phase 2 standards. Phase 1 data really just establishes that the target is engaged and acute tolerability is acceptable. We dont yet have efficacy data that would move a serious investigator from “interesting” to “important.” Long-term safety is a genuine unknown, HPG suppression is a real concern at pharmacological doses, and hepatic enzyme elevation signals at supratherapeutic exposures add caution flags for extended study designs.

As a bench tool, RAD-140 is actually quite useful. If you’re studying AR selectivity, differential co-activator biology, or SARM-class pharmacokinetics – that approximately 60-hour half-life is unusually long for the class – it gives you a high-signal probe. The widespread recreational use, frustrating from a regulatory standpoint, has generated a substantial body of observational pharmacokinetic data that investigators sometimes find valuable for dose-ranging rationale in study design.

We think this sits firmly in established-active territory. The breast cancer indication keeps it clinically relevant and worth watching; the mechanism maturity and evidence ceiling keep it from scoring higher.

Novelty

44

Mechanism promise

48

In-category differentiation

55

Evidence quality

48

Translational signal

50

Research bench value

58

Rationale RAD-140 earns its place as the benchmark high-potency SARM with actual phase 1/2 clinical data in AR-positive breast cancer, but tissue-selective AR agonism is a well-understood mechanism in an increasingly crowded class, and evidence quality stops well short of replicated phase 3 data.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Selective androgen receptor modulator (high-potency)

A potent non-steroidal SARM developed for muscle wasting and breast cancer; one of the highest-potency SARMs by binding affinity.

Abstract

Testolone (RAD-140; CAS 1182367-47-0; molecular formula C20H16ClN5O2; molecular weight 393.83) is a non-steroidal SARM developed by Radius Health for muscle wasting and (subsequently) AR-positive metastatic breast cancer. The compound is a high-potency AR ligand (Ki approximately 7 nM with high intrinsic activity) and a tissue-selective agonist; preclinical studies demonstrated anabolic activity in skeletal muscle exceeding that of testosterone propionate at equivalent molar doses, with reduced prostate effects. Phase 1 trials in postmenopausal women with metastatic breast cancer demonstrated dose-dependent AR pathway engagement; the program was advanced into phase 2. The compound is among the most widely used SARMs recreationally despite no regulatory approval. Plasma half-life is approximately 60 hours, supporting once-daily dosing. The principal safety concerns are HPG axis suppression and hepatic enzyme elevation at supratherapeutic doses; long-term safety data are absent.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-263Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
RU58841

Plain-language summaryIntrigue 55 / 100

RU58841 is a topical androgen receptor blocker developed by Roussel-Uclaf in the 1990s as a hair-loss treatment. The idea was elegant: rather than systemically lowering DHT (and risking sexual side effects), apply an AR blocker directly to the scalp where it competes with DHT at the hair follicle, with minimal absorption into the rest of the body. Phase 1 and 2 trials showed efficacy in slowing or reversing male-pattern baldness, but the compound was abandoned commercially (the reasons remain unclear and the compound was simply shelved). It is now used in DIY scalp solutions sourced as a research chemical, with minimal long-term safety data and no manufacturer accountability. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

41/100

A 1990s topical AR antagonist with real phase 2 data, now largely eclipsed by clascoterone

Look, RU58841 is a compound that almost made it. Roussel-Uclaf synthesized this hydantoin in the early 1990s with a genuinely smart idea behind it: get an AR antagonist into the scalp follicle without the systemic exposure that makes drugs like flutamide a liability. The structure binds the AR with enough affinity to compete with DHT locally, and if you keep it topical, you theoretically sidestep the sexual side effects that plagued oral antiandrogen use. Phase 1 and phase 2 trials were run, hair retention signals were real, and then the corporate machinery of a Sanofi merger ground the program to a halt. Not because it failed. Because priorities shifted.

That history matters for how we score it. We’ve got actual human data, which puts RU58841 ahead of a lot of compounds in this library that are still swimming in rodent studies. Phase 2 efficacy is real evidence. But the data is also thirty years old, never advanced to phase 3 confirmation, and hasnt been meaningfully replicated by independent groups in modern trial formats. What we have is a snapshot of mid-90s clinical pharmacology, not a living literature.

The bigger issue for differentiation is clascoterone. Cassiopea got Winlevi approved by the FDA in 2020, first as a topical AR antagonist for acne, and its been investigated for androgenetic alopecia since. That approval changes the landscape. RU58841 was the only reference topical AR antagonist for about two decades; now there’s a regulatory-approved alternative with a cleaner development history and ongoing Phase 2/3 AGA work. RU58841 doesn’t disappear from the toolbox, but it stops being the only option.

Where it still earns its keep is as a bench probe. If you’re studying follicular androgen biology, mapping AR occupancy in explant models, or trying to isolate DHT-mediated effects in scalp tissue, RU58841 is a well-characterized reference with published pharmacokinetics and selectivity data. Thats real utility for a narrow but serious research program. We dont dismiss that. But it’s probe value, not frontier value.

Honestly, the compound sits in a frustrating middle ground: too much evidence to call it speculative, not enough development to call it mature, and now partially overshadowed by a compound that finished what it started. A serious AGA researcher in 2025 would probably reach for clascoterone first and keep RU58841 as a backup reference tool. That’s the honest picture.

Novelty

20

Mechanism promise

35

In-category differentiation

45

Evidence quality

50

Translational signal

50

Research bench value

58

Rationale RU58841 scores low on novelty because it is a three-decade-old hydantoin developed at Roussel-Uclaf using straightforward single-receptor AR antagonism; its phase 2 human data lifts evidence and translational scores above most research peptides, but those gains are offset by commercial abandonment and the subsequent approval of clascoterone (Winlevi) as a topical AR antagonist, which erodes its differentiation. Bench value survives as a reference compound for follicular AR pharmacology, preventing a lower overall.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Topical androgen receptor antagonist

A topical non-steroidal AR antagonist developed for androgenetic alopecia; never advanced to commercial development but widely used as a research compound.

Abstract

RU58841 (PSK3841; CAS 154992-24-2; molecular formula C17H18F3N3O3; molecular weight 369.34) is a non-steroidal androgen receptor antagonist developed at Roussel-Uclaf (now Sanofi) in the 1990s as a topical treatment for androgenetic alopecia. The compound is structurally a hydantoin and binds the AR with sufficient affinity to compete with DHT in scalp tissue. Topical application allows local AR antagonism in hair follicles with minimal systemic absorption, theoretically avoiding the sexual side effects of systemic 5AR inhibitors. Phase 1 and 2 trials demonstrated efficacy in slowing or reversing scalp hair loss. Development was discontinued at Roussel-Uclaf (subsequent corporate merger and prioritization). The compound entered the research-grade and DIY hair loss community via the published patents and has remained in informal use without regulatory approval. Used as a reference topical AR antagonist in dermatologic and androgen pharmacology research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-281Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026

←Previous Page

1 … 64 65 66 67 68 69

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.